Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMFZBNE)

Drug Name
ITF2357 Drug Info
Synonyms Givinostat; Carbamic acid, N-(4-((hydroxyamino)carbonyl)phenyl)-, (6-((diethylamino)methyl)-2-naphthalenyl)methyl ester, hydrochloride (1:1)
Indication
Disease Entry ICD 11 Status REF
Duchenne dystrophy 8C70 Phase 3 [1]
Essential thrombocythemia 3B63.1Z Phase 2 [2] , [3]
Myelofibrosis 2A20.2 Phase 2 [2] , [3]
Polycythemia vera 2A20.4 Phase 2 [2] , [3]
Cross-matching ID
PubChem CID
9804992
ChEBI ID
CHEBI:94187
CAS Number
CAS 497833-27-9
TTD Drug ID
DMFZBNE

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Histone deacetylase (HDAC) TTBH0VX NOUNIPROTAC Inhibitor [1]
Histone deacetylase 1 (HDAC1) TT6R7JZ HDAC1_HUMAN Inhibitor [3] , [4]
Janus kinase 2 (JAK-2) TTRMX3V JAK2_HUMAN Inhibitor [3] , [4]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Janus kinase 2 (JAK-2) DTT JAK2 4.957 5.257 4.986 4.784
Histone deacetylase 1 (HDAC1) DTT HDAC1 6.206 8.094 7.236 7.56
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Duchenne dystrophy
ICD Disease Classification 8C70
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Histone deacetylase 1 (HDAC1) DTT HDAC1 5.21E-01 0.1 0.23
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7490).
3 Emerging drugs for the therapy of primary and post essential thrombocythemia, post polycythemia vera myelofibrosis. Expert Opin Emerg Drugs. 2009 Sep;14(3):471-9.
4 Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127.